NCT01283503CompletedPhase 1
A Phase I Study of BKM120, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- establish Maximum tolerate dose (MTD)
Study Overview
Brief Summary
In this study, BKM120 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will confirm the safety and tolerability and determine the maximum tolerated dose (MTD) of BKM120 in Japanese patients.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with histologically confirmed, advanced unresectable solid tumors who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists.
- •At least one measurable or non-measurable lesion as defined by RECIST guidelines for solid tumors.
- •Age ≥ 20 years
- •Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2
- •Life expectancy of ≥ 12 weeks
- •Patients must have the laboratory values
Exclusion Criteria
- •Patients with a history of primary central nervous system tumors or brain metastases or who have signs/symptoms attribute to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases
- •Prior treatment with a PI3K inhibitor
- •Patients with any peripheral neuropathy ≥ CTCAE grade 2
- •Patients with unresolved diarrhea ≥ CTCAE grade 2
- •Women of child-bearing potential who are pregnant or breast feeding. Men or women of reproductive potential not to sign informed consent for birth control. Barrier contraceptives must be used throughout the trial and six months after the end of treatment.
- •Other protocol-defined inclusion/exclusion criteria may apply
Arms & Interventions
BKM120
Experimental
Intervention: BKM120 (Drug)
Outcomes
Primary Outcomes
establish Maximum tolerate dose (MTD)
Time Frame: every day up to first 4 weeks
Secondary Outcomes
- Efficacy assessed by RECIST(Every 2 months)
- Establishment of a pharmacokinetic profile by collecting information on parameters including but not limited to Cmax, Tmax, T1/2 and AUC in plasma samples(Every 2 weeks up to first 4 weeks, then every odd cycle)
- Measurement of biomarkers for PI3K pathway in blood and tissue(First 4 weeks)
- Safety assessed by type, frequency and severity of adverse events(Every week)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid TumorsAdvanced Breast Cancer, Advanced Carcinomas With Squamous Cell HistologyNCT01626209Novartis Pharmaceuticals32
Withdrawn
Phase 2
BKM120 in Advanced, Metastatic, or Recurrent Endometrial CancersEndometrial CancerNCT01550380University of Utah
Completed
Phase 1
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast CancerEstrogen Receptor-positive Breast CancerRecurrent Breast CancerStage IV Breast CancerNCT01339442Washington University School of Medicine31
Completed
Phase 2
Safety and Efficacy of BKM120 in Relapsed and Refractory NHLDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaNCT01693614Novartis Pharmaceuticals72
Terminated
Phase 2
BKM120 in Metastatic Castration-resistant Prostate CancerMetastatic (Spread to Other Areas of the Body)Prostate CancerNCT01385293Andrew J. Armstrong, MD30